NCT06390657 2025-05-11
S-C-PATHY
EBG MedAustron GmbH
Withdrawn
Clinical Trials
34 trialsNCT06395090 2025-04-08
MK-9999-01B
Merck Sharp & Dohme LLC
Phase 1/2 Withdrawn
NCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT06377202 2024-11-07
Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies
Verismo Therapeutics
Withdrawn
NCT05678283 2024-04-17
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT04294875 2024-03-06
MPT0B64
J Ints Bio
Phase EARLY_PHASE1 Withdrawn
NCT05312307 2024-02-26
StrataEXPress
Strata Oncology
Withdrawn
NCT01632436 2023-10-02
Hepatic
CTI BioPharma
Phase 1 Withdrawn
NCT05828277 2023-09-26
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT02239575 2023-02-28
GBCPRT0009
Global BioClinical
Withdrawn
NCT04985825 2022-09-13
I-PACE
Centessa Pharmaceuticals plc
Phase 2 Withdrawn
NCT04809012 2022-03-25
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT03811418 2019-11-26
ATTILA
iOMEDICO AG
Phase 3 Withdrawn
NCT02939846 2018-09-14
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
GlaxoSmithKline
Phase 1 Withdrawn
NCT02705703 2018-08-28
Consolidation Therapy in Patients With Metastatic Solid Malignancies
Kiromic BioPharma Inc.
Phase 1/2 Withdrawn
NCT02674555 2017-07-28
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT00477425 2017-05-15
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Genentech, Inc.
Withdrawn
NCT02723838 2017-03-07
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Oncolytics Biotech
Phase 1 Withdrawn
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT02380313 2016-10-06
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
GlaxoSmithKline
Phase 1 Withdrawn
NCT02137811 2016-07-21
Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)
Pierian Biosciences
Withdrawn
NCT02292732 2016-01-26
A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Withdrawn
NCT00534807 2015-09-01
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00666081 2015-04-17
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
GlaxoSmithKline
Phase 1 Withdrawn
NCT00024674 2014-11-14
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days
INSYS Therapeutics Inc
Phase 1 Withdrawn
NCT00024687 2014-11-14
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
INSYS Therapeutics Inc
Phase 1 Withdrawn
NCT01636128 2014-07-30
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Cancer Prevention Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT01301612 2014-07-14
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Eurofarma Laboratorios S.A.
Phase 2 Withdrawn
NCT00923728 2014-01-10
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors
Vertex Pharmaceuticals Incorporated
Phase NA Withdrawn
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT01663415 2012-09-17
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc
Phase 2 Withdrawn
NCT00605709 2012-07-25
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma
BPGbio
Phase 2 Withdrawn
NCT00442741 2012-04-25
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
Novartis
Phase 1 Withdrawn
NCT01146171 2012-02-07
Japanese Phase 1 Study of BMS-844203 (CT322)
Bristol-Myers Squibb
Phase 1 Withdrawn